Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00074529
NCT00074529
Completed
Phase 2

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

Merck Sharp & Dohme LLC0 sites512 target enrollmentOctober 2003
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAlzheimer's Disease
DrugsMK0677

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Alzheimer's Disease
Sponsor
Merck Sharp & Dohme LLC
Enrollment
512
Primary Endpoint
Cognitive function over 12 month period; safety and tolerability
Status
Completed
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

Registry
clinicaltrials.gov
Start Date
October 2003
End Date
January 2006
Last Updated
10 years ago
Study Type
Interventional
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Cognitive function over 12 month period; safety and tolerability

Time Frame: over 12 month period

Secondary Outcomes

  • AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.(over a 6 month and 12 month period)

Similar Trials

Completed
Phase 2
Investigation of Memantine in the Treatment of Memory, Concentration or Attention ProblemsMemory DisorderRetention Disorder, CognitiveSubjective Cognitive ImpairmentMemory, Concentration or Attention Problems
NCT01261741Merz Pharmaceuticals GmbH299
Completed
Phase 2
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)Alzheimer's Disease
NCT00093951Saegis Pharmaceuticals280
Completed
Phase 2
Trial of Memantine for Cognitive Impairment in Multiple SclerosisMultiple SclerosisCognition Disorders
NCT00300716Oregon Health and Science University82
Completed
Phase 2
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.Alzheimers DiseaseDementiaAlzheimers Disease, Familial
NCT04623242Washington University School of Medicine194
Completed
Phase 2
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseCentral Nervous System DiseasesCognition
NCT01073228FORUM Pharmaceuticals Inc409